cardiovascular-agents and Thrombotic-Microangiopathies

cardiovascular-agents has been researched along with Thrombotic-Microangiopathies* in 3 studies

Other Studies

3 other study(ies) available for cardiovascular-agents and Thrombotic-Microangiopathies

ArticleYear
[Cardiac involvement in thrombotic microangiopathies].
    Terapevticheskii arkhiv, 2015, Volume: 87, Issue:9

    To describe cardiac involvement in patients with acute thrombotic microangiopathy (TMA).. The case histories of 46 patients with proven TMA, including 17 patients diagnosed with atypical hemolytic uremic syndrome (aHUS) and 29 patients with catastrophic antiphospholipid syndrome (CAPS), were analyzed.. Different documentarily verified signs of cardiac involvement were revealed in 6 (13%) patients (5 and 1 patients diagnosed as having aHUS and CAPS, respectively). Five patients developed myocardial involvement at disease onset in the presence of multiple organ dysfunction.. Cases of cardiac involvement in TMA of various genesis are presented. The exact incidence of myocardial involvement and its prognostic value are unknown so far.. Цель исследования. Описать поражение сердца у больных острой тромботической микроангиопатией (ТМА). Материалы и методы. Проанализировали 46 историй болезни пациентов с доказанной острой ТМА, из которых у 17 диагностирован атипичный гемолитико-уремический синдром (аГУС), у 29 - катастрофический антифосфолипидный синдром (КАФС). Результаты. Различные документально подтвержденные признаки поражения сердца выявлены у 6 (13%) больных (5 - с диагнозом аГУС, 1 - с КАФС). У 5 пациентов вовлечение миокарда развилось в дебюте заболевания в рамках полиорганного поражения. Заключение. Представлены наблюдения поражения сердца при ТМА разного генеза. Точная частота вовлечения миокарда и его прогностическое значение у пациентов с ТМА до настоящего времени неизвестны.

    Topics: Acute Disease; Adolescent; Adult; Antiphospholipid Syndrome; Atypical Hemolytic Uremic Syndrome; Cardiovascular Agents; Echocardiography; Electrocardiography; Female; Heart Diseases; Humans; Male; Renal Dialysis; Renal Insufficiency; Thrombotic Microangiopathies; Treatment Outcome

2015
A case series of the successful use of ECMO, continuous renal replacement therapy, and plasma exchange for thrombocytopenia-associated multiple organ failure.
    Journal of pediatric surgery, 2013, Volume: 48, Issue:5

    We present three cases of pediatric patients with thrombocytopenia-associated multiple organ failure and the evidence for providing extracorporeal organ support. All three patients had severe cardiac dysfunction, respiratory failure, and acute kidney injury treated with venoarterial extracorporeal membrane oxygenation, continuous renal replacement therapy, and plasma exchange. Despite the presence of multiple organ failure and high risk of mortality, all three patients survived with minimal long-term sequelae.

    Topics: ADAM Proteins; ADAMTS13 Protein; Adolescent; Bacteremia; Cardiopulmonary Resuscitation; Cardiovascular Agents; Child; Combined Modality Therapy; Extracorporeal Membrane Oxygenation; Fluid Therapy; Heart Arrest; Hemofiltration; Hemolytic-Uremic Syndrome; High-Frequency Ventilation; Humans; Infarction, Middle Cerebral Artery; Influenza A virus; Influenza, Human; Male; Methicillin-Resistant Staphylococcus aureus; Multiple Organ Failure; Osteomyelitis; Plasma Exchange; Staphylococcal Infections; Thrombotic Microangiopathies; Tracheostomy

2013
LINFAVENIX: improvement of signs and symptoms of chronic venous insufficiency and microangiopathy.
    Minerva cardioangiologica, 2008, Volume: 56, Issue:5 Suppl

    The aim of this independent study was to demonstrate the rapidity of the efficacy of an oral venotropic compound (Linfavenix, including natural elements) in patients with chronic venous insufficiency (CVI). Two groups of patients with chronic venous insufficiency (CVI) ankle swelling) were treated with Linfavenix or with below-knee elastic compression. The average ambulatory venous pressure (AVP) at inclusion (both groups)was 56.2 (range 48-55) with a refilling time (RT) shorter than 10 seconds. These parameters indicated a severe level of venous hypertension. There were no significant differences in AVP and RT between the two groups. The two groups of subjects with CVI were comparable; in the Linfavenix group there were 14 patients (age 44.5; sd 4; range 34-55; 7 females); in the elastic compression group there were 12 patients (45.4;5; range 36-56; 7 females). The clinical picture and microcirculatory parameters at inclusion were comparable. RF was comparable at inclusion in the two groups. At two weeks, the differences in RF (between goups) were not significant (the flux decreased in both groups, indicating improvement) while at 4 weeks the difference was larger (but non significant between the two groups) with a significant decrease in RF in the Linfavenix group. The RAS was also comparable at inclusion. Both groups had a significant decrease at 2 and 4 weeks. The decrease produced by Linfavenix after 4 weeks in RF was larger and significant (p<0.05) in comparison with the elastic compression group. Also the differences observed in ASLS were significant in both groups with an important, significant difference in favour of Linfavenix at 4 weeks (op<0.05) visibile as edema reduction. The decrease in edema was relevant in both groups at 2 (p<0.05) and 4 weeks (p<0.05) with a minimal but significant difference (p<0.05) between the Linfavenix and the elastic compression group. These variations in microcirculatory parameters indicate that the treatment with Linfavenix is, in its microcirculatory efficacy, at least comparable than elastic compression with is considered a standard therapeutic option in these patients. A significant level of improvement was reached with Linfavenix, in most patients (10/14) at 2 weeks for RF, at 7 days for the RAS and also at 2 weeks in almost all patients (13/14) considering ASLS and edema. No side effects due to treatment were observed. Compliance and tolerability were very good (no patient had to stop treatment; there were n

    Topics: Adult; Aesculus; Ankle; Cardiovascular Agents; Chronic Disease; Drug Combinations; Fagaceae; Female; Hamamelis; Humans; Male; Middle Aged; Nuts; Phytotherapy; Plant Preparations; Pyrus; Ruscus; Sorbus; Stockings, Compression; Thrombotic Microangiopathies; Treatment Outcome; Vaccinium myrtillus; Venous Insufficiency

2008